Dyne Therapeutics Inc. (DYN)
NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DYN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.90B
- EPS (TTM)
- -$3.62
- Dividend yield
- None
- 52-week range
- 14.00 – 27.31
- Day range
- 15.41 – 16.48
- Volume / Avg
- 2.23M / 2.94M
- Beta
- —
- Shares outstanding
- 187.39M
52-week range
DYN stock today
Shares of Dyne Therapeutics (DYN) finished lower on Nov 20 at $15.50, a drop of 3.31% or $0.53 per share, versus the S&P 500's 3.70% decline. Shares are 43.2% below their 52-week high of $27.31, set on Aug 12, 2026 and 10.7% above the 52-week low of $14.00, near the bottom of the past year's range. DYN is down 20.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 26.8%.
Dyne Therapeutics has posted a net loss over the last twelve months (EPS of -$3.62), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Dyne Therapeutics
Company profileDyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. John G. Cox M.B.A.
- Headquarters
- Waltham, MA
- Employees
- 322
- IPO year
- 2020
- Website
- dyne-tx.com
Financial highlights
Full financialsDyne Therapeutics reported a net loss of $446.2 million, compared with a loss of $317.4 million a year earlier. Diluted earnings per share came in at -$3.47.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-446.21M | $-317.42M | $-235.94M | $-168.10M | $-149.29M |
| EPS (diluted) | $-3.47 | $-3.37 | $-3.95 | $-3.23 | $-2.93 |
Analyst forecast
ForecastConsensus (17 analysts)
strong_buy
Avg. price target
$34.33+121.48%
- Strong buy 3
- Buy 12
- Hold 1
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.06 vs $-0.88
- Surprise
- -20.45%
DYN news
All DYN news- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Dyne Therapeutics to Participate in Upcoming Investor ConferenceGlobeNewswire
- Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Oversold Conditions For Dyne Therapeutics (DYN)Nasdaq
Dyne Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ACADACADIA Pharmaceuticals Inc. | 17.11 | -2.73% | $2.96B | vs DYN |
| LEGNLegend Biotech Corporation ADR | 15.25 | -5.28% | $2.96B | vs DYN |
| TLXTelix Pharmaceuticals Limited ADR | 8.37 | -3.90% | $2.84B | vs DYN |
| SLSSELLAS Life Sciences Group Inc. | 13.66 | -8.08% | $2.78B | vs DYN |
| BHCBausch Health Companies Inc. | 8.22 | -3.97% | $3.08B | vs DYN |
| XERSXeris Biopharma Holdings Inc. | 16.97 | +2.11% | $3.10B | vs DYN |
| VKTXViking Therapeutics Inc. | 24.77 | -4.14% | $3.16B | vs DYN |
| ABCLAbCellera Biologics Inc. | 9.69 | -7.45% | $3.16B | vs DYN |
Indexes, lists and sector
Dyne Therapeutics stock FAQ
What is Dyne Therapeutics's stock price today?
DYN last traded at $15.50 as of Nov 20, 4:00 PM EST, down 3.31% on the day. Prices are delayed at least 15 minutes.
Who is Dyne Therapeutics's CEO?
Mr. John G. Cox M.B.A. is the chief executive officer of Dyne Therapeutics Inc., which has about 322 employees.
What is the DYN 52-week high?
The 52-week high for DYN is $27.31 and the 52-week low is $14.00. The stock is currently 43.2% below its high.